Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Getting a diagnosis

Topic: Risk, prevention and care in population studies

The DRS-R-98, a 16-item clinician-rated scale with 13 severity items and 3 diagnostic items, was validated against the Cognitive Test for Delirium (CTD), Clinical Global Impression scale (CGI), and Delirium Rating Scale (DRS) among five diagnostic groups (N=68): delirium, dementia, depression, schizophrenia, and other. Mean and median DRS-R-98 scores significantly (P<0.001) distinguished delirium from each other group. DRS-R-98 total scores correlated highly with DRS, CTD, and CGI scores. Interrater reliability and internal consistency were very high. Cutoff scores for delirium are recommended based on ROC analyses (sensitivity and specificity ranges: total, 91%-100% and 85%-100%; severity, 86%-100% and 77%-93%, respectively, depending on the cutoffs or comparison groups chosen). The DRS-R-98 is a valid measure of delirium severity over a broad range of symptoms and is a useful diagnostic and assessment tool. The DRS-R-98 is ideal for longitudinal studies.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Trzepacz, P. T., Mittal, D., Torres, R., Kanary, K., Norton, J., & Jimerson, N. (2001). Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. The Journal of neuropsychiatry and clinical neurosciences. https://doi.org/10.1176/jnp.13.2.229

Vancouver

Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. The Journal of neuropsychiatry and clinical neurosciences. 2001. doi:10.1176/jnp.13.2.229. PMID: 11449030.

BibTeX

@article{trzepacz2001-11449030,
  author  = {Trzepacz, P. T. and Mittal, D. and Torres, R. and Kanary, K. and Norton, J. and Jimerson, N.},
  title   = {{Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium}},
  journal = {The Journal of neuropsychiatry and clinical neurosciences},
  year    = {2001},
  doi     = {10.1176/jnp.13.2.229},
  pmid    = {11449030},
  url     = {https://doi.org/10.1176/jnp.13.2.229}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study validated the Delirium Rating Scale-revised-98, finding that its scores distinguished delirium from other groups including dementia and that it is a useful diagnostic and assessment tool. It concerns assessment of delirium and reports nothing about treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 58/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 3 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 56 of the 96 points it could be judged on, which is 58 of 100. Total 58 of 100.56 of the 96 points we could judge = 58 of 100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 56 of the 96 points we could judge it on, which is 58 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Journal of neuropsychiatry and clinical neurosciences)
Journal's citation record 2 / 4 Journal of Neuropsychiatry: journal h-index 155 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2001 — older than 20 years, still counted
Sample size 1 / 4 68 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 955 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 35.4 citations a year over 27 year(s) since 2001
Impact for its field and year 3 / 6 Cited 4.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 11 other studies in this library
Still being cited 3 / 4 Cited 114 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Nita Jimerson holds only 5 work(s), too few to judge a track record — left out of this score
Institution's track record 1 / 3 Eli Lilly (United States): institution h-index 744 (OpenAlex)
Multi-centre collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 11449030)
Free to read 0 / 2 Behind a paywall — scores zero
Points 56 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 56 of the 96 points we could judge it on is 58 out of 100.
Total 58 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Later studies that cite this one

11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis

Also tagged “delirium”

858 studies in the library carry the topic tag “delirium”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →